Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Corcept Therapeutics (CORT) Net Income towards Common Stockholders: 2009-2024

Historic Net Income towards Common Stockholders for Corcept Therapeutics (CORT) over the last 12 years, with Dec 2024 value amounting to $139.7 million.

  • Corcept Therapeutics' Net Income towards Common Stockholders fell 58.54% to $19.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $104.6 million, marking a year-over-year decrease of 25.50%. This contributed to the annual value of $139.7 million for FY2024, which is 32.45% up from last year.
  • Per Corcept Therapeutics' latest filing, its Net Income towards Common Stockholders stood at $139.7 million for FY2024, which was up 32.45% from $105.5 million recorded in FY2023.
  • Corcept Therapeutics' Net Income towards Common Stockholders' 5-year high stood at $139.7 million during FY2024, with a 5-year trough of $101.3 million in FY2022.
  • Its 3-year average for Net Income towards Common Stockholders is $115.5 million, with a median of $105.5 million in 2023.
  • Per our database at Business Quant, Corcept Therapeutics' Net Income towards Common Stockholders declined by 9.98% in 2022 and then spiked by 32.45% in 2024.
  • Corcept Therapeutics' Net Income towards Common Stockholders (Yearly) stood at $106.0 million in 2020, then increased by 6.13% to $112.5 million in 2021, then dropped by 9.98% to $101.3 million in 2022, then rose by 4.15% to $105.5 million in 2023, then spiked by 32.45% to $139.7 million in 2024.